← 홈

Antibody

1,830개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-10 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,830개
AntibodystaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRuijin HospitalPhase 2

Zanubrutinib + Rituximab + MTX ± Selinexor (Zanubrutinib + Rituximab + MTX ± Selinexor)

Central Nervous System Lymphoma · Central Nervous System Lymphoma

#CentralNervousSystemLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleFirst Affiliated Hospital of We…Phase 2

Zanubrutinib+Rituximab+Lenalidomide (Zanubrutinib+Rituximab+Lenalidomide)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleInstitute of Hematology & Blood…Phase 2

Zanubrutinib, Bendamustine and Rituximab (Zanubrutinib, Bendamustine and Rituximab)

Waldenstrom Macroglobulinemia · Waldenstrom Macroglobulinemia

#WaldenstromMacroglobulinemia#Antibody#Phase2#항체#면역항체+2
효능 ORR 66.4%임상시험 1상태 RECRUITING
AntibodystaleInstitute of Hematology & Blood…Phase 2

Zanubrutinib, Fludarabine, cyclophosphamide and rituximab (Zanubrutinib, Fludarabine, cyclophosphamide and rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

ZR2 (Zanubrutinib, Lenalidomide and Rituximab, Zanubrutinib, Lenalidomide and Rituximab (ZR2))

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleInstitute of Hematology & Blood…Phase 2

Zanubrutinib, bendamustine, rituximab (Zanubrutinib, bendamustine, rituximab)

Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystalePeking UniversityPhase 2

Zanubrutinib, high-dose methotrexate (HD-MTX, Zanubrutinib, high-dose methotrexate, Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab)

Secondary Central Nervous System Lymphoma · Secondary Central Nervous System Lymphom

#SecondaryCentralNervousSystemLym#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleThe First Affiliated Hospital w…Phase 2

Zebetuzumab (Zebetuzumab)

Marginal Zone Lymphoma(MZL) · Marginal Zone Lymphoma(MZL)

#MarginalZoneLymphomaMZL#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleMerus B.V.Phase 2

Zenocutuzumab (Zenocutuzumab)

Breast Cancer Metastatic · Breast Cancer Metastatic

#BreastCancerMetastatic#Antibody#Phase2#항체#면역항체+2
효능 ORR 0%임상시험 1상태 ACTIVE
AntibodystaleGilead SciencesPhase 2

ZIM (Zimberelimab, Zimberelimab (ZIM))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Lung Cancer

#LungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleNational Cancer Institute (NCI)Phase 1

aflibercept (Eylea, VEGF Trap-Eye, Eylea HD, Ziv-Aflibercept)

Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Colorectal Carcinoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleJules Bordet InstitutePhase 1

trastuzumab (Herceptin, Zr89-trastuzumab)

Breast Neoplasms; Secondary · HER2

#HER2#Antibody#Phase1#항체#면역항체+4
효능 ORR 10%임상시험 1상태 ACTIVE
AntibodystaleOu Bai, MDPhase 2

Zuberitamab-CHOP+orelabrutinib (Zuberitamab-CHOP+orelabrutinib)

DLBCL - Diffuse Large B Cell Lymphoma · DLBCL - Diffuse Large B Cell Lymphoma

#DLBCL-DiffuseLargeBCellLymphoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleM.D. Anderson Cancer CenterPhase 2

^111 In Ibritumomab Tiuxetan (^111 In Ibritumomab Tiuxetan)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 0.8%임상시험 1상태 DISCONTINUED
AntibodystaleUniversity Hospital, Strasbourg…Approved

abatacept, rituximab or tocilizumab (abatacept, rituximab or tocilizumab)

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleAbbVieApproved

up to 9 months exposure (adalimumab, adalimumab (up to 9 months exposure))

Rheumatoid Arthritis · Rheumatoid Arthritis

#RheumatoidArthritis#Antibody#Approved#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleAbbViePreclinical

adalimumab (Humira, adalimumab and methotrexate)

Psoriasi · Psoriasi

#Psoriasi#Antibody#Preclinical#항체#면역항체+2
효능 ORR 6.35%임상시험 1상태 ACTIVE

81 / 92 페이지

← 이전다음 →